In addition to general articles on clinical aspects of diabetes mellitus, Diabetes and Metabolic Syndrome: Clinical Research and Reviews also presents articles on basic research in all areas of diabetes and the metabolic syndrome. Topics include prevention, diagnosis, pathogenesis, clinical management of diabetes and all its complications, including neuropathy, retinopathy, nephropathy, peripheral vascular disease, foot problems (amongst others), as well as atherosclerotic cardiovascular disease. All aspects of disorders associated with the metabolic syndrome with a special emphasis on clinical aspects (prevalence, pathogenesis, risk factors management and prevention, etc.) of comorbid conditions such as hypertension, obesity, dyslipidemias and atherosclerotic cardiovascular disease are also of relevance to the journal. Diabetes and Metabolic Syndrome: Clinical Research and Reviews also publishes papers on the general pathogenesis and prevention of diabetes.
Criteria for initial considerations for papers submitted will be originality, statistical rigour, and relevance to the aims of the journal. All manuscripts of interest will be subjected to the process of peer review. Initially all submissions are reviewed internally by members of the Editorial Board and all submissions which pass this stage are then subjected to an external peer-review process. Please include names and contact details for six individuals as suggested reviewers for the manuscript, for use at the Editors' discretion.
All manuscripts submitted to Diabetes and Metabolic Syndrome: Clinical Research and Reviews should report original research not previously published or being considered for publication elsewhere, make explicit any conflict of interest, identify sources of funding and generally be of a high ethical standard.
Even where consent has been given, identifying details should be omitted if they are not essential. Complete anonymity is difficult to achieve. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Article Types
These are either written or commissioned by the Editors and should not exceed 1000 words (not including a maximum of 20 references; one small figure can be included).Commentaries
They (1000 words not including a maximum of 20 references and one small figure) offer a stimulating, journalistic and accessible insight into issues of common interest. They are usually commissioned by the Editors but unsolicited articles will be considered. Debates comprise two commentaries of opposing or contrasting opinion written by two different groups of authors. Controversial opinions are welcomed as long as they are set in the context of the generally accepted view.Original Research Articles
These should be a maximum of 5000 words. The word limit includes a maximum of five figures or tables with legends, but does not include up to 50 references and an abstract of up to 200 words structured according to Aims, Methods, Results, Conclusions and Keywords. Divide the manuscript into the following sections: Title Page; Structured Abstract; Introduction; Subjects, Materials and Methods; Results; Discussion; Acknowledgements; References; figures and tables with legends.Brief Reports
These reports should not exceed 1000 words, including a summary of no more than 50 words (but not including up to 20 references) and may be a preliminary report of work completed, a final report or an observation not requiring a lengthy write-up.Review articles
Review articles should be a maximum of 5000 words, including a summary of no more than 100 words (not including up to 75 references) with subheadings in the text to highlight the content of different sections. Reviews are generally commissioned by the Editors but unsolicited articles will be considered.Letters to the Editor
These should be no more than 400 words.Contact details for submission
If assistance is required by the authors, please refer to the EVISE Author Guide at http://supportcontent.elsevier.com/Support%20Hub/Documents/EVISE_Beta_User_Guide_Author.pdf; you may also contact the Editorial Office. Please do not post, fax or e-mail your manuscripts to the Editorial Office.
Work on human beings that is submitted to the journal should comply with the principles laid down in the Declaration of Helsinki "Recommendations guiding physicians in biomedical research involving human subjects", adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964 (and its successive amendments). The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed. Studies involving experiments with animals must state that their care was in accordance with institution guidelines.
Authors are required to disclose commercial or similar relationships to products or companies mentioned in or related to the subject matter of the article being submitted. Sources of funding for the article should be acknowledged in a footnote on the title page. Affiliations of authors should include corporate appointments relating to or in connection with products or companies mentioned in the article, or otherwise bearing on the subject matter thereof. Other pertinent financial relationships, such as consultancies, stock ownership or other equity interests or patent-licensing arrangements, should be disclosed to the Editor-in-Chief in the cover letter at the time of submission. Such relationships may be disclosed in the Journal at the discretion of the Editor-in-Chief.
All randomised controlled trials submitted to Diabetes and Metabolic Syndrome: Clinical Research and Reviews whose primary purpose is to affect clinical practice (phase 3 trials) must be registered in accordance with the principles outlined by the International Committee of Medical Journal Editors (ICMJE; http://www.icmje.org/). ICJME-approved registries currently include the following: 'ClinicalTrials.gov'; 'www.ISRCTN.org '; 'www.actr.org.au '; 'www.umin.ac.jp '; and 'www.trialregister.nl '. Please include the unique trial number and registry name on manuscript submission.
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our green open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.
This journal has an embargo period of 12 months. Publisher Services
Proofs will be sent to the authors for careful checking. Corrected proofs should be returned to the publisher within stated deadlines.
Elsevier will do everything possible to get your article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication. Subsequent corrections will not be possible, so please ensure your communication is complete.Fast-track Publication: The journal aims for prompt publication of all accepted papers. Submissions containing new and particularly important data may be fast-tracked for peer review and publication; this is a limited facility and is strictly at the discretion of the Editors.
Page Charges are not made.Submission
We have now upgraded our submission system from EES to EVISE. However articles that are submitted to EES would still be processed in EES and to know the current status of your submission on EES, please contact the Journal Manager at: email@example.com.
Submit your article
Please submit your article via http://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL_ACR=DMSCRR.
This journal operates a double blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.
On the title page, include title; subtitle (if any); first name, middle initial, and last names of each author, with academic degrees; name of Department(s) and Institution(s) to which the work should be attributed; name and address of author to whom requests for reprints should be sent. The address, telephone and fax numbers of the person responsible for negotiations concerning the manuscripts should be listed separately and clearly labelled as such. Authors will be required to sign a statement conferring the manuscript copyright to Diabetes and Metabolic Syndrome: Clinical Research and Reviews.
Abstract and Keywords
A structured abstract of 100 to 250 words for articles (including Reviews), or 50 to 100 words for Brief Communications, should be provided. It should cover the main factual points, including statements of the problem, methods, results, and conclusions. The abstract should be accompanied by a list of three to five keywords for indexing purposes.
Headings and subheadings should be provided in the Methods and Results sections, and where appropriate in the discussion. Please keep the text clear, concise and free of jargon.
Abbreviations, Numbers and SI Units
Authors should limit the use of abbreviations. Terms which are mentioned frequently may be abbreviated but only if this does not detract from reader comprehension. The abbreviation should be defined after the first use of the term.
Figures must be suitable for high-quality reproduction. Lettering should be complete, of professional quality, and of a size appropriate to that of the illustration or drawing, with the necessary reduction in size taken into account. If, together with your accepted article, you submit usable colour figures, Elsevier will ensure that these figures appear free-of-charge in colour in the electronic version of your accepted article. Colour illustrations can only be included in print if the additional cost of reproduction is contributed by the author: you will receive information regarding the costs from Elsevier after receipt of your accepted article.
Tables should be numbered consecutively with Arabic numerals. Provide a short descriptive heading and explanation above each table with a legend. Symbols for units should be confined to column headings. Abbreviations should be kept to a minimum, and when used, explained fully.
Number the references in the order in which they first appear in the text and identify the reference numbers in the text in superscript. References must be placed at the end of the manuscript. Please use recent references as much as possible. The responsibility for accuracy of references lies with the respective authors. The Journal is in agreement with the International Committee of Medical Journal Editors ( http://www.icmje.org). The general arrangement, abbreviations of Journal names and punctuations followed are as per the Uniform Requirements for Manuscripts submitted to Biomedical Journals ( http://www.icmje.org ). Please pay attention to the style of references and punctuations as follows:
List all authors when six or less as shown in the example below:
When there are seven or more authors, list only the first six and add et al.
[dataset]  Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. http://dx.doi.org/10.17632/xwj98nb39r.1
Following is an example: Cassidy JT. Juvenile rheumatoid arthritis. In: Textbook of Rheumatology 6th ed, Kelly et al (eds) Philadelphia Saunders 2000; pp. 1297–313.
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. This identifier will not appear in your published article.
Authors may submit additional supportive applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. Offprints
The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on ScienceDirect. This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (http://webshop.elsevier.com/myarticleservices/offprints. Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (http://webshop.elsevier.com/myarticleservices/offprints/myarticlesservices/booklets.
Special Subject Repositories Certain repositories such as PubMed Central ('PMC') are authorized under special arrangement with Elsevier to process and post certain articles. The following agreements have been established for authors whose articles have been accepted for publication in an Elsevier journal and whose underlying research is supported by one of the following funding bodies:• National Institutes of Health: Elsevier will send a version of the author's accepted manuscript that includes author revisions following peer-review for public access posting 12 months after final publication. Because the NIH 'Public Access' policy is voluntary, authors may elect not to deposit such articles in PMC. If you wish to 'opt out' and not deposit to PMC, you may indicate this by sending an e-mail to NIHauthorrequest@elsevier.com. More information regarding the agreement between Elsevier and the National Institutes of Health can be found at http://www.elsevier.com/about/open-science/open-access/agreements/elsevier-nih-policy-statement
• The Wellcome Trust: Elsevier will send to PMC the version of the author's manuscript that reflects all author-agreed changes including those made post peer review, for public access posting immediately after final publication. Authors are required to initially subsidize their manuscript with fees reimbursed by the Wellcome Trust. Wellcome Trust authors, whose manuscripts are subsidized, will have the corresponding articles made free to non-subscribers on ScienceDirect www.sciencedirect.com and Elsevier's electronic publishing platforms. More information regarding the agreement between Elsevier and The Wellcome Trust can be found at http://www.elsevier.com/about/open-science/open-access/agreements/elsevier-agreement-with-the-wellcome-trust
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.